Verona_Pharma_Dark_medium.jpg
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
January 24, 2022 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subset
January 05, 2022 02:00 ET | Verona Pharma plc
ENHANCE-2 Screening Complete with Full Enrollment Expected in January 2022 ENHANCE Phase 3 Program on Track to Report Top-line Data in 2022 LONDON and RALEIGH, N.C., Jan. 05, 2022 (GLOBE...
Verona_Pharma_Dark_medium.jpg
Verona Pharma to Present at H.C. Wainwright BioConnect Virtual Conference
January 04, 2022 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Reports TQT Study Successfully Demonstrated No Clinically Relevant Effect on Cardiac Conduction
December 16, 2021 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 09, 2021 02:00 ET | Verona Pharma plc
Enrollment in ENHANCE-1 48-week subset and ENHANCE-2 expected to complete around year-end 2021ENHANCE Phase 3 program on track to report top-line data in 2022Conference call today at 9:00 a.m....
Verona_Pharma_Dark_medium.jpg
Verona Pharma Announces November 2021 Investor Conference Participation
November 01, 2021 03:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona_Pharma_Dark_medium.jpg
Verona Pharma to Report Third Quarter 2021 Financial Results and Provide Corporate Update
October 26, 2021 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona_Pharma_Dark_medium.jpg
Verona Pharma to Present Phase 2 Data with pMDI Ensifentrine in COPD at CHEST 2021
October 13, 2021 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Presents Pharmacokinetic Data with Ensifentrine at the European Respiratory Society International Congress 2021
September 02, 2021 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona_Pharma_Dark_medium.jpg
Verona Pharma to Present at H.C. Wainwright 23rd Annual Global Investment Conference
August 31, 2021 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...